Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections.

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• * Pseudomonas infections lead to high rates of illness and death.
• * These bacteria can cause sepsis and exhibit multidrug resistance.
• * Treating Pseudomonas infections is challenging due to complex clinical, microbiological, and pharmacological factors.

Purpose of the Study:

• * To review current literature on intravenous fosfomycin for Pseudomonas infections.
• * To discuss its epidemiological, microbiological, and clinical data.
• * To evaluate its potential as a repurposed antimicrobial therapy.

Main Methods:

• * Comprehensive literature review of studies on intravenous fosfomycin.
• * Analysis of pharmacokinetic/pharmacodynamic properties.
• * Evaluation of antibiofilm activity and synergistic effects.

Main Results:

• * Intravenous fosfomycin demonstrates favorable pharmacokinetic/pharmacodynamic profiles for various infections.
• * It possesses significant antibiofilm activity.
• * It exhibits synergistic effects when combined with other antimicrobials.

Conclusions:

• * Intravenous fosfomycin is a promising therapeutic option for Pseudomonas infections.
• * Its repurposing in combination therapy warrants further investigation.
• * It offers a potential solution for multidrug-resistant Pseudomonas strains.